Humoral and cellular responses to spike of δ SARS-CoV-2 variant in vaccinated patients with immune-mediated inflammatory diseases
•The cellular response to δ SARS-CoV-2 variant is present in vaccinated patients with immune-mediated inflammatory disease (IMID)•The cellular response magnitude to δ SARS-CoV-2 variant depend on the type of therapy•The serological response was similar between the patients with IMID and the control...
Saved in:
| Published in | International journal of infectious diseases Vol. 121; pp. 24 - 30 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Canada
Elsevier Ltd
01.08.2022
The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases Elsevier |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | •The cellular response to δ SARS-CoV-2 variant is present in vaccinated patients with immune-mediated inflammatory disease (IMID)•The cellular response magnitude to δ SARS-CoV-2 variant depend on the type of therapy•The serological response was similar between the patients with IMID and the control group
We assessed vaccination-induced antibody and cellular responses against spike from the ancestral strain and from the delta (δ) SARS-CoV-2 variant in patients with immune-mediated inflammatory diseases (IMIDs) on immunosuppressive therapy in comparison with immunocompetent subjects.
We enrolled patients with IMID and immunocompetent subjects who completed the vaccination schedule within 4–6 months from the first dose. The interferon (IFN)-γ-response to spike peptides that were derived from the ancestral and the δ SARS-CoV-2 were measured by ELISA. Anti-Receptor Binding Domain IgG antibodies were also evaluated.
We enrolled 43 patients with IMID and nine immunocompetent subjects. No significant differences were found after comparing the specific immune response (IFN-γ) between patients with IMID and immunocompetent subjects to the ancestral (p = 0.36) or δ peptide pool (p = 0.51). Nevertheless, IFN-γ-specific responses to the ancestral or to the δ pools were reduced in subjects taking CTLA4-IgG or TNF-α inhibitors compared with subjects treated with IL-6 inhibitors or Disease Modifying Anti-Rheumatic Drugs. Regarding the antibody response, no significant differences were observed between patients with IMID and immunocompetent individuals.
Cellular responses to δ SARS-CoV-2 variant remain largely intact in patients with IMID. However, the magnitude of these responses is dependent on the specific IMID immunosuppressive regimen. Serological response was also similar between the IMID and control groups.
[Display omitted] |
|---|---|
| AbstractList | Objectives: We assessed vaccination-induced antibody and cellular responses against spike from the ancestral strain and from the delta (δ) SARS-CoV-2 variant in patients with immune-mediated inflammatory diseases (IMIDs) on immunosuppressive therapy in comparison with immunocompetent subjects. Methods: We enrolled patients with IMID and immunocompetent subjects who completed the vaccination schedule within 4–6 months from the first dose. The interferon (IFN)-γ-response to spike peptides that were derived from the ancestral and the δ SARS-CoV-2 were measured by ELISA. Anti-Receptor Binding Domain IgG antibodies were also evaluated. Results: We enrolled 43 patients with IMID and nine immunocompetent subjects. No significant differences were found after comparing the specific immune response (IFN-γ) between patients with IMID and immunocompetent subjects to the ancestral (p = 0.36) or δ peptide pool (p = 0.51). Nevertheless, IFN-γ-specific responses to the ancestral or to the δ pools were reduced in subjects taking CTLA4-IgG or TNF-α inhibitors compared with subjects treated with IL-6 inhibitors or Disease Modifying Anti-Rheumatic Drugs. Regarding the antibody response, no significant differences were observed between patients with IMID and immunocompetent individuals. Conclusions: Cellular responses to δ SARS-CoV-2 variant remain largely intact in patients with IMID. However, the magnitude of these responses is dependent on the specific IMID immunosuppressive regimen. Serological response was also similar between the IMID and control groups. We assessed vaccination-induced antibody and cellular responses against spike from the ancestral strain and from the delta (δ) SARS-CoV-2 variant in patients with immune-mediated inflammatory diseases (IMIDs) on immunosuppressive therapy in comparison with immunocompetent subjects. We enrolled patients with IMID and immunocompetent subjects who completed the vaccination schedule within 4-6 months from the first dose. The interferon (IFN)-γ-response to spike peptides that were derived from the ancestral and the δ SARS-CoV-2 were measured by ELISA. Anti-Receptor Binding Domain IgG antibodies were also evaluated. We enrolled 43 patients with IMID and nine immunocompetent subjects. No significant differences were found after comparing the specific immune response (IFN-γ) between patients with IMID and immunocompetent subjects to the ancestral (p = 0.36) or δ peptide pool (p = 0.51). Nevertheless, IFN-γ-specific responses to the ancestral or to the δ pools were reduced in subjects taking CTLA4-IgG or TNF-α inhibitors compared with subjects treated with IL-6 inhibitors or Disease Modifying Anti-Rheumatic Drugs. Regarding the antibody response, no significant differences were observed between patients with IMID and immunocompetent individuals. Cellular responses to δ SARS-CoV-2 variant remain largely intact in patients with IMID. However, the magnitude of these responses is dependent on the specific IMID immunosuppressive regimen. Serological response was also similar between the IMID and control groups. We assessed vaccination-induced antibody and cellular responses against spike from the ancestral strain and from the delta (δ) SARS-CoV-2 variant in patients with immune-mediated inflammatory diseases (IMIDs) on immunosuppressive therapy in comparison with immunocompetent subjects.OBJECTIVESWe assessed vaccination-induced antibody and cellular responses against spike from the ancestral strain and from the delta (δ) SARS-CoV-2 variant in patients with immune-mediated inflammatory diseases (IMIDs) on immunosuppressive therapy in comparison with immunocompetent subjects.We enrolled patients with IMID and immunocompetent subjects who completed the vaccination schedule within 4-6 months from the first dose. The interferon (IFN)-γ-response to spike peptides that were derived from the ancestral and the δ SARS-CoV-2 were measured by ELISA. Anti-Receptor Binding Domain IgG antibodies were also evaluated.METHODSWe enrolled patients with IMID and immunocompetent subjects who completed the vaccination schedule within 4-6 months from the first dose. The interferon (IFN)-γ-response to spike peptides that were derived from the ancestral and the δ SARS-CoV-2 were measured by ELISA. Anti-Receptor Binding Domain IgG antibodies were also evaluated.We enrolled 43 patients with IMID and nine immunocompetent subjects. No significant differences were found after comparing the specific immune response (IFN-γ) between patients with IMID and immunocompetent subjects to the ancestral (p = 0.36) or δ peptide pool (p = 0.51). Nevertheless, IFN-γ-specific responses to the ancestral or to the δ pools were reduced in subjects taking CTLA4-IgG or TNF-α inhibitors compared with subjects treated with IL-6 inhibitors or Disease Modifying Anti-Rheumatic Drugs. Regarding the antibody response, no significant differences were observed between patients with IMID and immunocompetent individuals.RESULTSWe enrolled 43 patients with IMID and nine immunocompetent subjects. No significant differences were found after comparing the specific immune response (IFN-γ) between patients with IMID and immunocompetent subjects to the ancestral (p = 0.36) or δ peptide pool (p = 0.51). Nevertheless, IFN-γ-specific responses to the ancestral or to the δ pools were reduced in subjects taking CTLA4-IgG or TNF-α inhibitors compared with subjects treated with IL-6 inhibitors or Disease Modifying Anti-Rheumatic Drugs. Regarding the antibody response, no significant differences were observed between patients with IMID and immunocompetent individuals.Cellular responses to δ SARS-CoV-2 variant remain largely intact in patients with IMID. However, the magnitude of these responses is dependent on the specific IMID immunosuppressive regimen. Serological response was also similar between the IMID and control groups.CONCLUSIONSCellular responses to δ SARS-CoV-2 variant remain largely intact in patients with IMID. However, the magnitude of these responses is dependent on the specific IMID immunosuppressive regimen. Serological response was also similar between the IMID and control groups. •The cellular response to δ SARS-CoV-2 variant is present in vaccinated patients with immune-mediated inflammatory disease (IMID)•The cellular response magnitude to δ SARS-CoV-2 variant depend on the type of therapy•The serological response was similar between the patients with IMID and the control group We assessed vaccination-induced antibody and cellular responses against spike from the ancestral strain and from the delta (δ) SARS-CoV-2 variant in patients with immune-mediated inflammatory diseases (IMIDs) on immunosuppressive therapy in comparison with immunocompetent subjects. We enrolled patients with IMID and immunocompetent subjects who completed the vaccination schedule within 4–6 months from the first dose. The interferon (IFN)-γ-response to spike peptides that were derived from the ancestral and the δ SARS-CoV-2 were measured by ELISA. Anti-Receptor Binding Domain IgG antibodies were also evaluated. We enrolled 43 patients with IMID and nine immunocompetent subjects. No significant differences were found after comparing the specific immune response (IFN-γ) between patients with IMID and immunocompetent subjects to the ancestral (p = 0.36) or δ peptide pool (p = 0.51). Nevertheless, IFN-γ-specific responses to the ancestral or to the δ pools were reduced in subjects taking CTLA4-IgG or TNF-α inhibitors compared with subjects treated with IL-6 inhibitors or Disease Modifying Anti-Rheumatic Drugs. Regarding the antibody response, no significant differences were observed between patients with IMID and immunocompetent individuals. Cellular responses to δ SARS-CoV-2 variant remain largely intact in patients with IMID. However, the magnitude of these responses is dependent on the specific IMID immunosuppressive regimen. Serological response was also similar between the IMID and control groups. [Display omitted] Image, graphical abstract |
| Author | Sebastiani, Gian Domenico Nicastri, Emanuele Castilletti, Concetta Picchianti-Diamanti, Andrea Sette, Alessandro Laganà, Bruno Aiello, Alessandra Meschi, Silvia Vanini, Valentina Vaia, Francesco Gualano, Gina Grifoni, Alba Goletti, Delia Petrone, Linda Ferraioli, Mario Cuzzi, Gilda |
| Author_xml | – sequence: 1 givenname: Linda surname: Petrone fullname: Petrone, Linda organization: Translational Research Unit, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, 00149 Rome, Italy – sequence: 2 givenname: Andrea surname: Picchianti-Diamanti fullname: Picchianti-Diamanti, Andrea organization: Department of Clinical and Molecular Medicine, "Sapienza" University, S. Andrea University Hospital, 00189 Rome, Italy – sequence: 3 givenname: Gian Domenico surname: Sebastiani fullname: Sebastiani, Gian Domenico organization: Department of Rheumatology, San Camillo Hospital, 00152 Rome, Italy – sequence: 4 givenname: Alessandra orcidid: 0000-0003-2681-9383 surname: Aiello fullname: Aiello, Alessandra organization: Translational Research Unit, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, 00149 Rome, Italy – sequence: 5 givenname: Bruno surname: Laganà fullname: Laganà, Bruno organization: Department of Clinical and Molecular Medicine, "Sapienza" University, S. Andrea University Hospital, 00189 Rome, Italy – sequence: 6 givenname: Gilda surname: Cuzzi fullname: Cuzzi, Gilda organization: Translational Research Unit, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, 00149 Rome, Italy – sequence: 7 givenname: Valentina surname: Vanini fullname: Vanini, Valentina organization: Translational Research Unit, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, 00149 Rome, Italy – sequence: 8 givenname: Gina surname: Gualano fullname: Gualano, Gina organization: Respiratory Infectious Diseases Unit, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, 00149 Rome, Italy – sequence: 9 givenname: Alba surname: Grifoni fullname: Grifoni, Alba organization: Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA, 92037, USA – sequence: 10 givenname: Mario surname: Ferraioli fullname: Ferraioli, Mario organization: Rheumatology, Allergology and Clinical Immunology, Dipartimento di medicina dei sistemi, University of Rome Tor Vergata, Rome, Italy – sequence: 11 givenname: Concetta orcidid: 0000-0001-9819-236X surname: Castilletti fullname: Castilletti, Concetta organization: Virology Unit, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, 00149 Rome, Italy – sequence: 12 givenname: Silvia surname: Meschi fullname: Meschi, Silvia organization: Virology Unit, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, 00149 Rome, Italy – sequence: 13 givenname: Francesco surname: Vaia fullname: Vaia, Francesco organization: UOC Direzione Sanitaria, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, 00149 Rome, Italy – sequence: 14 givenname: Emanuele surname: Nicastri fullname: Nicastri, Emanuele organization: UOC Malattie Infettive ad Alta Intensità di Cura, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, 00149 Rome, Italy – sequence: 15 givenname: Alessandro surname: Sette fullname: Sette, Alessandro organization: Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA, 92037, USA – sequence: 16 givenname: Delia orcidid: 0000-0001-8360-4376 surname: Goletti fullname: Goletti, Delia email: delia.goletti@inmi.it organization: Translational Research Unit, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, 00149 Rome, Italy |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35462039$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFUstuFDEQHKEg8oAf4IB85DKLX2N7EEKKVkAiRUIiwNVqezyJNzP2Ys9utFe-ie_gm_BmE0RyCCe33F1V6q46rPZCDK6qXhI8I5iIN4uZX_huRjGlM8xnmMon1QFRUtWsIWSv1BSTupWE7leHOS8wxlwI9azaZw0XFLP2oPp5shpjggFB6JB1w7AaIKHk8jKG7DKaIspLf-VQ7NHvX-j8-Mt5PY_fa4rWkDyECflQSmt9gMl1aAmTd2HK6NpPl8iP4yq4enSdv-n60A8wjjDFtEGdzw6KxvPqaQ9Ddi9u36Pq28cPX-cn9dnnT6fz47PaciVlbRRxPW-dbAwRklvGAUsLghPacUa4JaJtMGmV6E2HjVKylbgTjvUMKBjFjqrTHW8XYaGXyY-QNjqC1zcfMV1oSJO3g9OM9U3bQ28JBm5aA5KQzhEluDGmMaZwvd9xLVembGfLyuWI90jvd4K_1BdxrVtMGRNNIXh9S5Dij5XLkx593t4fgourrKloGoIbrGQZffWv1l-ROxPLgNoN2BRzTq7X1k_Fh7iV9oMmWG_zohd6mxe9zYvGXJe8FCh9AL1jfxT0bgdyxa21d0lnW0y3xeXk7FTO6R-Hv30At4MP3sJw5Tb_A_8B7M_vjQ |
| CitedBy_id | crossref_primary_10_3389_fimmu_2022_920227 crossref_primary_10_1016_j_biopha_2024_117153 crossref_primary_10_1002_cpz1_934 crossref_primary_10_1016_j_vaccine_2023_05_041 crossref_primary_10_1016_j_jinf_2024_106402 crossref_primary_10_3389_fmed_2022_997876 crossref_primary_10_1099_jgv_0_002055 crossref_primary_10_1016_j_ijid_2022_10_035 crossref_primary_10_1016_j_ijid_2022_07_049 crossref_primary_10_3390_pathogens12070862 crossref_primary_10_3390_vaccines12070786 crossref_primary_10_3389_fimmu_2023_1244556 crossref_primary_10_3390_v14112541 crossref_primary_10_1016_j_lanepe_2024_100979 crossref_primary_10_1038_s41598_023_50263_5 crossref_primary_10_36425_rehab637448 crossref_primary_10_1016_j_isci_2022_105209 crossref_primary_10_1136_rmdopen_2022_002632 crossref_primary_10_3389_fimmu_2023_1146704 crossref_primary_10_1038_s41541_024_00805_3 crossref_primary_10_1146_annurev_immunol_101721_061120 crossref_primary_10_1002_ctm2_1171 crossref_primary_10_1002_hsr2_2250 crossref_primary_10_1093_cei_uxae044 crossref_primary_10_1136_jnnp_2022_330175 crossref_primary_10_3389_fimmu_2022_984098 crossref_primary_10_3390_v15051132 crossref_primary_10_3389_fonc_2024_1290614 crossref_primary_10_1016_j_vaccine_2023_08_033 |
| Cites_doi | 10.3390/microorganisms9061315 10.1126/science.abn4947 10.3390/jcm10112388 10.1056/NEJMc2107799 10.3389/fimmu.2021.740249 10.3390/microorganisms9071542 10.1016/j.jinf.2021.02.023 10.1016/j.ijid.2021.02.090 10.1056/NEJMoa2108891 10.2807/1560-7917.ES.2021.26.24.2100509 10.1002/art.27584 10.1016/j.cell.2021.01.007 10.7326/M21-1451 10.3389/fneur.2022.881988 10.1016/j.ijid.2021.04.034 10.1155/2015/763461 10.1016/j.cmi.2020.09.051 10.1038/s41586-022-04411-y 10.1136/bmj.n1088 10.1038/s41591-022-01700-x 10.7326/M21-1757 10.1136/annrheumdis-2021-220597 10.3389/fimmu.2021.747830 10.1007/s40265-020-01421-w 10.1097/BOR.0000000000000491 10.1016/j.cmi.2021.07.005 |
| ContentType | Journal Article |
| Copyright | 2022 The Author(s) Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved. 2022 The Author(s) 2022 |
| Copyright_xml | – notice: 2022 The Author(s) – notice: Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved. – notice: 2022 The Author(s) 2022 |
| DBID | 6I. AAFTH AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM DOA |
| DOI | 10.1016/j.ijid.2022.04.027 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Open Access Full Text |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ (Directory of Open Access Journals) url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Public Health |
| EISSN | 1878-3511 |
| EndPage | 30 |
| ExternalDocumentID | oai_doaj_org_article_33f59fafc10a4b9ba711de1864bbb5bb PMC9023365 35462039 10_1016_j_ijid_2022_04_027 S1201971222002296 |
| Genre | Journal Article |
| GroupedDBID | --- --K .1- .FO .~1 0R~ 1B1 1P~ 1~. 1~5 29J 3O- 4.4 457 4G. 53G 5GY 5VS 7-5 71M 7X7 88E 8C1 8FI 8FJ 8FQ 8R4 8R5 AAEDW AAFWJ AAIKJ AALRI AAQFI AAQXK AARKO AAXUO AAYWO ABBQC ABFRF ABMAC ABUWG ABWVN ACGFO ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO ADVLN AEFWE AEKER AENEX AEUPX AEVXI AEXQZ AFJKZ AFKRA AFPKN AFPUW AFRHN AFTJW AGEKW AGHFR AGQPQ AGYEJ AHMBA AIGII AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ APXCP ASPBG AVWKF AZFZN BAWUL BCNDV BENPR BPHCQ BR6 BVXVI CCPQU CS3 DIK DU5 DWQXO E3Z EBS EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FNPLU FYUFA G-Q GBLVA GROUPED_DOAJ GX1 HMCUK HVGLF HZ~ IHE IXB J1W KQ8 M1P M3C M3G M41 MO0 N9A O-L O9- OD- OK1 OO. OZT P-8 P-9 P2P PC. PHGZM PHGZT PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO Q2X Q38 QTD R2- ROL RPZ RWL RXW SDF SDG SEL SES SEW SSZ TAE UKHRP UNMZH Z5R 0SF 3V. 6I. AACTN AAFTH ABVKL AFCTW NCXOZ RIG AAYXX ALIPV CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c4877-b81ef49e75b1674c34a07ca6412d4314c169501986fbd0b887970d6e3f3a2ab83 |
| IEDL.DBID | DOA |
| ISSN | 1201-9712 1878-3511 |
| IngestDate | Wed Aug 27 01:16:53 EDT 2025 Thu Aug 21 18:16:17 EDT 2025 Fri Jul 11 10:58:50 EDT 2025 Mon Jul 21 05:59:34 EDT 2025 Tue Jul 01 04:30:13 EDT 2025 Thu Apr 24 23:04:59 EDT 2025 Fri Feb 23 02:40:44 EST 2024 Tue Aug 26 16:32:08 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | COVID-19 vaccine immune response IMID T- cell response |
| Language | English |
| License | This is an open access article under the CC BY-NC-ND license. Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4877-b81ef49e75b1674c34a07ca6412d4314c169501986fbd0b887970d6e3f3a2ab83 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 these authors equally contributed |
| ORCID | 0000-0001-9819-236X 0000-0003-2681-9383 0000-0001-8360-4376 |
| OpenAccessLink | https://doaj.org/article/33f59fafc10a4b9ba711de1864bbb5bb |
| PMID | 35462039 |
| PQID | 2655105087 |
| PQPubID | 23479 |
| PageCount | 7 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_33f59fafc10a4b9ba711de1864bbb5bb pubmedcentral_primary_oai_pubmedcentral_nih_gov_9023365 proquest_miscellaneous_2655105087 pubmed_primary_35462039 crossref_citationtrail_10_1016_j_ijid_2022_04_027 crossref_primary_10_1016_j_ijid_2022_04_027 elsevier_sciencedirect_doi_10_1016_j_ijid_2022_04_027 elsevier_clinicalkey_doi_10_1016_j_ijid_2022_04_027 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2022-08-01 |
| PublicationDateYYYYMMDD | 2022-08-01 |
| PublicationDate_xml | – month: 08 year: 2022 text: 2022-08-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Canada |
| PublicationPlace_xml | – name: Canada |
| PublicationTitle | International journal of infectious diseases |
| PublicationTitleAlternate | Int J Infect Dis |
| PublicationYear | 2022 |
| Publisher | Elsevier Ltd The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases Elsevier |
| Publisher_xml | – name: Elsevier Ltd – name: The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases – name: Elsevier |
| References | WHO. WHO announces simple, easy-to-say labels for SARS-CoV-2 Variants of Interest and Concern, 2021. Campbell, Archer, Laurenson-Schafer, Jinnai, Konings, Batra (bib0006) 2021; 26 Aletaha, Neogi, Silman, Funovits, Felson, Bingham (bib0003) 2010; 62 Bonelli, Scheinecker (bib0005) 2018; 30 Haberman, Herati, Simon, Samanovic, Blank, Tuen (bib0018) 2021; 80 Lopez Bernal, Andrews, Gower, Gallagher, Simmons, Thelwall (bib0020) 2021; 385 Sette, Crotty (bib0029) 2021; 184 Cantini, Goletti, Petrone, Najafi Fard, Niccoli, Foti (bib0007) 2020; 80 Aiello, Najafi Fard, Petruccioli, Petrone, Vanini, Farroni (bib0002) 2021; 106 Pulliam, van Schalkwyk, Govender, von Gottberg, Cohen, Groome (bib0028) 2022; 15 WHO. COVID-19 Weekly Epidemiological Update Edition 74 2022. Connolly, Boyarsky, Ruddy, Werbel, Christopher-Stine, Garonzik-Wang (bib0012) 2021; 174 Petrone, Tortorella, Aiello, Farroni, Ruggieri, Castilletti (bib0023) 2022 Gao, Cai, Grifoni, Müller, Niessl, Olofsson (bib0016) 2022 Petrone, Petruccioli, Alonzi, Vanini, Cuzzi, Najafi Fard (bib0024) 2021; 82 Goletti, Petrone, Manissero, Bertoletti, Rao, Ndunda (bib0017) 2021; 27 Cassaniti, Bergami, Percivalle, Gabanti, Sammartino, Ferrari (bib0009) 2021 Belleudi, Rosa, Poggi, Armuzzi, Nicastri, Goletti (bib0004) 2021; 10 Edara, Pinsky, Suthar, Lai, Davis-Gardner, Floyd (bib0015) 2021; 385 Carrasco Pro, Sidney, Paul, Lindestam Arlehamn, Weiskopf, Peters (bib0008) 2015; 2015 Melo-González, Soto, González, Fernández, Duarte, Schultz (bib0022) 2021; 12 Picchianti-Diamanti, Aiello, Laganà, Agrati, Castilletti, Meschi (bib0027) 2021; 12 Deepak, Kim, Paley, Yang, Carvidi, Demissie (bib0013) 2021; 174 Agrati, Castilletti, Goletti, Meschi, Sacchi, Matusali (bib0001) 2021; 9 Collier, Yu, Mcmahan, Liu, Atyeo, Ansel (bib0011) 2021 Despres, Mills, Shirley, Schmidt, Huang, Jerome (bib0014) 2021 Jyssum, Kared, Tran, Tveter, Provan, Sexton (bib0019) 2021 Lopez Bernal, Andrews, Gower, Robertson, Stowe, Tessier (bib0021) BMJ 2021; 373 Cherian, Potdar, Jadhav, Yadav, Gupta, Das (bib0010) 2021; 9 Petrone, Petruccioli, Vanini, Cuzzi, Gualano, Vittozzi (bib0025) 2021; 113 Viana, Moyo, Amoako, Tegally, Scheepers, Althaus (bib0030) 2022 Petrone, Petruccioli, Vanini, Cuzzi, Najafi Fard, Alonzi (bib0026) 2021; 27 Carrasco Pro (10.1016/j.ijid.2022.04.027_bib0008) 2015; 2015 Lopez Bernal (10.1016/j.ijid.2022.04.027_bib0021) 2021; 373 Jyssum (10.1016/j.ijid.2022.04.027_bib0019) 2021 Haberman (10.1016/j.ijid.2022.04.027_bib0018) 2021; 80 Collier (10.1016/j.ijid.2022.04.027_bib0011) 2021 10.1016/j.ijid.2022.04.027_bib0031 Melo-González (10.1016/j.ijid.2022.04.027_bib0022) 2021; 12 10.1016/j.ijid.2022.04.027_bib0032 Pulliam (10.1016/j.ijid.2022.04.027_bib0028) 2022; 15 Lopez Bernal (10.1016/j.ijid.2022.04.027_bib0020) 2021; 385 Goletti (10.1016/j.ijid.2022.04.027_bib0017) 2021; 27 Gao (10.1016/j.ijid.2022.04.027_bib0016) 2022 Despres (10.1016/j.ijid.2022.04.027_bib0014) 2021 Cherian (10.1016/j.ijid.2022.04.027_bib0010) 2021; 9 Belleudi (10.1016/j.ijid.2022.04.027_bib0004) 2021; 10 Petrone (10.1016/j.ijid.2022.04.027_bib0024) 2021; 82 Aletaha (10.1016/j.ijid.2022.04.027_bib0003) 2010; 62 Cassaniti (10.1016/j.ijid.2022.04.027_bib0009) 2021 Sette (10.1016/j.ijid.2022.04.027_bib0029) 2021; 184 Bonelli (10.1016/j.ijid.2022.04.027_bib0005) 2018; 30 Deepak (10.1016/j.ijid.2022.04.027_bib0013) 2021; 174 Picchianti-Diamanti (10.1016/j.ijid.2022.04.027_bib0027) 2021; 12 Petrone (10.1016/j.ijid.2022.04.027_bib0025) 2021; 113 Cantini (10.1016/j.ijid.2022.04.027_bib0007) 2020; 80 Agrati (10.1016/j.ijid.2022.04.027_bib0001) 2021; 9 Viana (10.1016/j.ijid.2022.04.027_bib0030) 2022 Petrone (10.1016/j.ijid.2022.04.027_bib0026) 2021; 27 Connolly (10.1016/j.ijid.2022.04.027_bib0012) 2021; 174 Edara (10.1016/j.ijid.2022.04.027_bib0015) 2021; 385 Petrone (10.1016/j.ijid.2022.04.027_bib0023) 2022 Campbell (10.1016/j.ijid.2022.04.027_bib0006) 2021; 26 Aiello (10.1016/j.ijid.2022.04.027_bib0002) 2021; 106 |
| References_xml | – volume: 80 start-page: 1929 year: 2020 end-page: 1946 ident: bib0007 article-title: Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review publication-title: Drugs – volume: 385 start-page: 585 year: 2021 end-page: 594 ident: bib0020 article-title: Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant publication-title: N Engl J Med – volume: 12 year: 2021 ident: bib0027 article-title: ImmunosuppressiveTherapies Differently Modulate Humoral- and T-Cell-Specific Responses to COVID-19 mRNA Vaccine in Rheumatoid Arthritis Patients publication-title: Front Immunol – volume: 2015 year: 2015 ident: bib0008 article-title: Automatic Generation of Validated Specific Epitope Sets publication-title: J Immunol Res – volume: 27 start-page: 286 year: 2021 ident: bib0026 article-title: A whole blood test to measure SARS-CoV-2-specific response in COVID-19 patients publication-title: Clin Microbiol Infect – year: 2022 ident: bib0030 article-title: Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa publication-title: Nature – volume: 80 start-page: 1339 year: 2021 end-page: 1344 ident: bib0018 article-title: Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease publication-title: Ann Rheum Dis – year: 2021 ident: bib0009 article-title: Humoral and cell-mediated response against SARS-CoV-2 variants elicited by mRNA vaccine BNT162b2 in healthcare workers: a longitudinal observational study publication-title: Clin Microbiol Infect – year: 2021 ident: bib0019 article-title: Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study publication-title: Lancet Rheumatol – year: 2022 ident: bib0016 article-title: Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant publication-title: Nat Med – volume: 9 start-page: 1542 year: 2021 ident: bib0010 article-title: SARS-CoV-2 Spike Mutations, L452R, T478K, E484Q and P681R, in the Second Wave of COVID-19 in Maharashtra publication-title: India. Microorganisms – volume: 385 start-page: 664 year: 2021 end-page: 666 ident: bib0015 article-title: Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants publication-title: N Engl J Med – volume: 82 start-page: 58 year: 2021 end-page: 66 ident: bib0024 article-title: In-vitro evaluation of the immunomodulatory effects of Baricitinib: Implication for COVID-19 therapy publication-title: J Infect – volume: 26 year: 2021 ident: bib0006 article-title: Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021 publication-title: Euro Surveill – volume: 9 start-page: 1315 year: 2021 ident: bib0001 article-title: Coordinate Induction of Humoral and Spike Specific T-Cell Response in a Cohort of Italian Health Care Workers Receiving BNT162b2 mRNA publication-title: Vaccine. Microorganisms – volume: 113 start-page: S82 year: 2021 end-page: S87 ident: bib0025 article-title: Coinfection of tuberculosis and COVID-19 limits the ability to in vitro respond to SARS-CoV-2 publication-title: Int J Infect Dis – volume: 174 start-page: 1572 year: 2021 end-page: 1585 ident: bib0013 article-title: Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2: A Prospective Cohort Study publication-title: Ann Intern Med – volume: 373 start-page: n1088 year: BMJ 2021 ident: bib0021 article-title: Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study publication-title: BMJ – year: 2022 ident: bib0023 article-title: Humoral and cellular response to spike of Delta SARS-CoV-2 variant in vaccinated patients with Multiple Sclerosis publication-title: Front Neurology – volume: 62 start-page: 2569 year: 2010 end-page: 2581 ident: bib0003 article-title: 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative publication-title: Arthritis Rheum – volume: 12 year: 2021 ident: bib0022 article-title: Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine publication-title: Front Immunol – volume: 174 start-page: 1332 year: 2021 end-page: 1334 ident: bib0012 article-title: Absence of Humoral Response After Two-Dose SARS-CoV-2 Messenger RNA Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: A Case Series publication-title: Ann Intern Med – year: 2021 ident: bib0014 article-title: Quantitative measurement of infectious virus in SARS-CoV-2 Alpha, Delta and Epsilon variants reveals higher infectivity (viral titer:RNA ratio) in clinical samples containing the Delta and Epsilon variants publication-title: medRxiv – volume: 27 start-page: 1784 year: 2021 end-page: 1789 ident: bib0017 article-title: The potential clinical utility of measuring severe acute respiratory syndrome coronavirus 2-specific T-cell responses publication-title: Clin Microbiol Infect – volume: 10 start-page: 2388 year: 2021 ident: bib0004 article-title: Direct and Indirect Impact of COVID-19 for Patients with Immune-Mediated Inflammatory Diseases: A Retrospective Cohort Study publication-title: J Clin Med – year: 2021 ident: bib0011 article-title: COVID-19 mRNA Vaccine Immunogenicity in Immunosuppressed Individuals publication-title: J Infect Dis – reference: WHO. COVID-19 Weekly Epidemiological Update Edition 74 2022. – reference: WHO. WHO announces simple, easy-to-say labels for SARS-CoV-2 Variants of Interest and Concern, 2021. – volume: 15 start-page: eabn4947 year: 2022 ident: bib0028 article-title: Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa publication-title: Science – volume: 184 start-page: 861 year: 2021 end-page: 880 ident: bib0029 article-title: Adaptive immunity to SARS-CoV-2 and COVID-19 publication-title: Cell – volume: 30 start-page: 295 year: 2018 end-page: 300 ident: bib0005 article-title: How does abatacept really work in rheumatoid arthritis? publication-title: Curr Opin Rheumatol – volume: 106 start-page: 338 year: 2021 end-page: 347 ident: bib0002 article-title: Spike is the most recognized antigen in the whole-blood platform in both acute and convalescent COVID-19 patients publication-title: Int J Infect Dis – volume: 9 start-page: 1315 year: 2021 ident: 10.1016/j.ijid.2022.04.027_bib0001 article-title: Coordinate Induction of Humoral and Spike Specific T-Cell Response in a Cohort of Italian Health Care Workers Receiving BNT162b2 mRNA publication-title: Vaccine. Microorganisms doi: 10.3390/microorganisms9061315 – volume: 15 start-page: eabn4947 year: 2022 ident: 10.1016/j.ijid.2022.04.027_bib0028 article-title: Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa publication-title: Science doi: 10.1126/science.abn4947 – volume: 10 start-page: 2388 year: 2021 ident: 10.1016/j.ijid.2022.04.027_bib0004 article-title: Direct and Indirect Impact of COVID-19 for Patients with Immune-Mediated Inflammatory Diseases: A Retrospective Cohort Study publication-title: J Clin Med doi: 10.3390/jcm10112388 – ident: 10.1016/j.ijid.2022.04.027_bib0032 – volume: 385 start-page: 664 year: 2021 ident: 10.1016/j.ijid.2022.04.027_bib0015 article-title: Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants publication-title: N Engl J Med doi: 10.1056/NEJMc2107799 – year: 2021 ident: 10.1016/j.ijid.2022.04.027_bib0009 article-title: Humoral and cell-mediated response against SARS-CoV-2 variants elicited by mRNA vaccine BNT162b2 in healthcare workers: a longitudinal observational study publication-title: Clin Microbiol Infect – volume: 12 year: 2021 ident: 10.1016/j.ijid.2022.04.027_bib0027 article-title: ImmunosuppressiveTherapies Differently Modulate Humoral- and T-Cell-Specific Responses to COVID-19 mRNA Vaccine in Rheumatoid Arthritis Patients publication-title: Front Immunol doi: 10.3389/fimmu.2021.740249 – volume: 9 start-page: 1542 year: 2021 ident: 10.1016/j.ijid.2022.04.027_bib0010 article-title: SARS-CoV-2 Spike Mutations, L452R, T478K, E484Q and P681R, in the Second Wave of COVID-19 in Maharashtra publication-title: India. Microorganisms doi: 10.3390/microorganisms9071542 – volume: 82 start-page: 58 year: 2021 ident: 10.1016/j.ijid.2022.04.027_bib0024 article-title: In-vitro evaluation of the immunomodulatory effects of Baricitinib: Implication for COVID-19 therapy publication-title: J Infect doi: 10.1016/j.jinf.2021.02.023 – volume: 113 start-page: S82 year: 2021 ident: 10.1016/j.ijid.2022.04.027_bib0025 article-title: Coinfection of tuberculosis and COVID-19 limits the ability to in vitro respond to SARS-CoV-2 publication-title: Int J Infect Dis doi: 10.1016/j.ijid.2021.02.090 – volume: 385 start-page: 585 year: 2021 ident: 10.1016/j.ijid.2022.04.027_bib0020 article-title: Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant publication-title: N Engl J Med doi: 10.1056/NEJMoa2108891 – volume: 26 year: 2021 ident: 10.1016/j.ijid.2022.04.027_bib0006 article-title: Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021 publication-title: Euro Surveill doi: 10.2807/1560-7917.ES.2021.26.24.2100509 – volume: 62 start-page: 2569 year: 2010 ident: 10.1016/j.ijid.2022.04.027_bib0003 article-title: 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative publication-title: Arthritis Rheum doi: 10.1002/art.27584 – volume: 184 start-page: 861 year: 2021 ident: 10.1016/j.ijid.2022.04.027_bib0029 article-title: Adaptive immunity to SARS-CoV-2 and COVID-19 publication-title: Cell doi: 10.1016/j.cell.2021.01.007 – year: 2021 ident: 10.1016/j.ijid.2022.04.027_bib0014 article-title: Quantitative measurement of infectious virus in SARS-CoV-2 Alpha, Delta and Epsilon variants reveals higher infectivity (viral titer:RNA ratio) in clinical samples containing the Delta and Epsilon variants publication-title: medRxiv – volume: 174 start-page: 1332 year: 2021 ident: 10.1016/j.ijid.2022.04.027_bib0012 article-title: Absence of Humoral Response After Two-Dose SARS-CoV-2 Messenger RNA Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: A Case Series publication-title: Ann Intern Med doi: 10.7326/M21-1451 – year: 2022 ident: 10.1016/j.ijid.2022.04.027_bib0023 article-title: Humoral and cellular response to spike of Delta SARS-CoV-2 variant in vaccinated patients with Multiple Sclerosis publication-title: Front Neurology doi: 10.3389/fneur.2022.881988 – volume: 106 start-page: 338 year: 2021 ident: 10.1016/j.ijid.2022.04.027_bib0002 article-title: Spike is the most recognized antigen in the whole-blood platform in both acute and convalescent COVID-19 patients publication-title: Int J Infect Dis doi: 10.1016/j.ijid.2021.04.034 – volume: 2015 year: 2015 ident: 10.1016/j.ijid.2022.04.027_bib0008 article-title: Automatic Generation of Validated Specific Epitope Sets publication-title: J Immunol Res doi: 10.1155/2015/763461 – ident: 10.1016/j.ijid.2022.04.027_bib0031 – volume: 27 start-page: 286 year: 2021 ident: 10.1016/j.ijid.2022.04.027_bib0026 article-title: A whole blood test to measure SARS-CoV-2-specific response in COVID-19 patients publication-title: Clin Microbiol Infect doi: 10.1016/j.cmi.2020.09.051 – year: 2022 ident: 10.1016/j.ijid.2022.04.027_bib0030 article-title: Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa publication-title: Nature doi: 10.1038/s41586-022-04411-y – year: 2021 ident: 10.1016/j.ijid.2022.04.027_bib0019 article-title: Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study publication-title: Lancet Rheumatol – volume: 373 start-page: n1088 year: 2021 ident: 10.1016/j.ijid.2022.04.027_bib0021 article-title: Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study publication-title: BMJ doi: 10.1136/bmj.n1088 – year: 2022 ident: 10.1016/j.ijid.2022.04.027_bib0016 article-title: Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant publication-title: Nat Med doi: 10.1038/s41591-022-01700-x – volume: 174 start-page: 1572 year: 2021 ident: 10.1016/j.ijid.2022.04.027_bib0013 article-title: Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2: A Prospective Cohort Study publication-title: Ann Intern Med doi: 10.7326/M21-1757 – volume: 80 start-page: 1339 year: 2021 ident: 10.1016/j.ijid.2022.04.027_bib0018 article-title: Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2021-220597 – volume: 12 year: 2021 ident: 10.1016/j.ijid.2022.04.027_bib0022 article-title: Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine publication-title: Front Immunol doi: 10.3389/fimmu.2021.747830 – volume: 80 start-page: 1929 year: 2020 ident: 10.1016/j.ijid.2022.04.027_bib0007 article-title: Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review publication-title: Drugs doi: 10.1007/s40265-020-01421-w – volume: 30 start-page: 295 year: 2018 ident: 10.1016/j.ijid.2022.04.027_bib0005 article-title: How does abatacept really work in rheumatoid arthritis? publication-title: Curr Opin Rheumatol doi: 10.1097/BOR.0000000000000491 – year: 2021 ident: 10.1016/j.ijid.2022.04.027_bib0011 article-title: COVID-19 mRNA Vaccine Immunogenicity in Immunosuppressed Individuals publication-title: J Infect Dis – volume: 27 start-page: 1784 year: 2021 ident: 10.1016/j.ijid.2022.04.027_bib0017 article-title: The potential clinical utility of measuring severe acute respiratory syndrome coronavirus 2-specific T-cell responses publication-title: Clin Microbiol Infect doi: 10.1016/j.cmi.2021.07.005 |
| SSID | ssj0004668 |
| Score | 2.4472005 |
| Snippet | •The cellular response to δ SARS-CoV-2 variant is present in vaccinated patients with immune-mediated inflammatory disease (IMID)•The cellular response... We assessed vaccination-induced antibody and cellular responses against spike from the ancestral strain and from the delta (δ) SARS-CoV-2 variant in patients... Image, graphical abstract Objectives: We assessed vaccination-induced antibody and cellular responses against spike from the ancestral strain and from the delta (δ) SARS-CoV-2 variant... |
| SourceID | doaj pubmedcentral proquest pubmed crossref elsevier |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 24 |
| SubjectTerms | Antibodies, Viral Antibody Formation COVID-19 COVID-19 - prevention & control Humans IMID immune response Immunity, Humoral Immunoglobulin G SARS-CoV-2 T- cell response vaccine |
| SummonAdditionalLinks | – databaseName: Elsevier SD Freedom Collection dbid: .~1 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Nj9MwELVWe0BICMHyVRaQkbgh0zh2nPi4VKxWSHCgLNqbZcc2ZBeSqu3ukQO_id_Bb2ImcaoWpEXi1iZ24nReZyb2vGdCXmhhQ2mDZJ7nnkE8jszlQjLnlYf8xOJiG1ZbvFcnp_LtWXG2R2YjFwbLKpPvH3x6763TkWn6NaeLppnOOcQuXXIIcBiINMpuS1kiyl9951vcyIEOB40Ztk7EmaHGqzlvUC00z3u5U9xZZis49Rr-OzHq7xz0z1LKrdh0fIfcTkklPRrGfZfshfaA3HiXls0PyK1hco4OnKN75AcYEZn51Lae4tQ91qLS5VAuG1Z03dHVorkItIv01086P_owZ7PuE8vpFbxagy1o08LHGq4OqaqnSZx1RXFWlzZIOQms56TgWcAwwO5bv5xP04LQ6j45PX7zcXbC0mYMrIZ3mpK5iocodSgLh8SFWkiblbVVEmwMSYisudIFGKRS0fnMge_SZeZVEFHY3LpKPCD7bdeGR4Q6VcSQRVe5oKXyQec-qCpqlB-TQrgJ4aMVTJ2UynHDjK9mLEk7N2g5g5YzmTRguQl5uemzGHQ6rm39Go27aYka2_2BbvnZJJAZIWKho401B8g67WzJuQ-8UtI5VzgYphihYUYaKzheuFBz7a2LTa8doP-z3_MRfQY8AGLDtqG7XJlcFZglZxW0eTigcfNgopAqz4SekHIHpztPvnumbb70KuMasjmhisf_Od5DchO_DbWST8j-enkZnkL-tnbP-j_ob4rTRM8 priority: 102 providerName: Elsevier |
| Title | Humoral and cellular responses to spike of δ SARS-CoV-2 variant in vaccinated patients with immune-mediated inflammatory diseases |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S1201971222002296 https://dx.doi.org/10.1016/j.ijid.2022.04.027 https://www.ncbi.nlm.nih.gov/pubmed/35462039 https://www.proquest.com/docview/2655105087 https://pubmed.ncbi.nlm.nih.gov/PMC9023365 https://doaj.org/article/33f59fafc10a4b9ba711de1864bbb5bb |
| Volume | 121 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Nb9QwELWgB4SEKihfW6AyEjdkSGzHiY9tRVVAIEEp2ptlx7aaAknV3XLkwG_id_CbmImTaBek9sIlihI7kTMvnmd75pmQZ1rYUNogmc-5Z-CPI3NcSOa88sBPLC62YbTFe3V4LN_Mi_nKVl8YE5bkgdOHeylELHS0sc6hotPOlnnuQ14p6ZwrnMPeF3zeOJiaMiJTEhy4N6bLnA_pMimyqzltUCOU817kFPeTWXFJvXL_mmf6l3n-HUC54pEObpPNgUrS3dSEO-RaaLfIjXfDYvkWuZWm5GjKNLpLfoLpMB-f2tZTnLDHCFR6noJkw4IuO7o4a74E2kX6-xc92v14xPa7z4zT7zCgBgvQpoXTGp4OBNXTQZJ1QXEulzaYaBJYn4mCdwG5ALZv_SI-HZaBFvfI8cGrT_uHbNiCgdUwkimZq_IQpQ5l4TBdoRbSZmVtlQTLAvWQda50ASyxUtH5zEGPpcvMqyCisNy6StwnG23XhoeEOlXEkEVXuaCl8kFzH1QVNYqOSSHcjOSjFUw96JPjNhlfzRiIdmrQcgYtZzJpwHIz8nyqc5bUOS4tvYfGnUqisnZ_AfBmBryZq_A2I2KEhhmTV6G7hQc1l766mGoN1CZRlivrPR3RZ-C_R2zYNnQXC8NVgdw4q6DMg4TGqWGikIpnQs9IuYbTtZav32mbk15bXAOHE6rY_h-f6hG5iU1J4ZKPycby_CI8AQq3dDvk-osf-U7_z8Lx9XwPjm8_VH8Ag8VI-A |
| linkProvider | Directory of Open Access Journals |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELZKkQAJISiv5WkkbshsHDtOfCwrqgJtD2yLerPs2IYUSFa7W44c-E38Dn4TM3msdkEqErcoHidO5svMxJ5vTMhzLWzIbZDM89Qz8MeRuVRI5rzyEJ9YXGzDbIsjtX8i355mp1tkMnBhMK2yt_2dTW-tdX9m3L_N8ayqxlMOvkvnHBwcOiKtLpHLEj5f3Mbg5Xe-Ro7s-HAgzVC8Z850SV7VWYXlQtO0rXeKW8useae2iP-Gk_o7CP0zl3LNOe3dJDf6qJLudgO_RbZCvUOuHPbr5jvkejc7RzvS0W3yA7SI1Hxqa09x7h6TUem8y5cNC7ps6GJWfQ60ifTXTzrdfT9lk-YDS-k3-LcGZdCqhsMSrg6xqqd9ddYFxWldWiHnJLCWlIKtAGLA3dd2PZ_2K0KLO-Rk7_XxZJ_1uzGwEn5qcuYKHqLUIc8cMhdKIW2Sl1ZJUDJEIbLkSmegkUJF5xMHxkvniVdBRGFT6wpxl2zXTR3uE-pUFkMSXeGClsoHnfqgiqix_pgUwo0IH7Rgyr5UOe6Y8cUMOWlnBjVnUHMmkQY0NyIvVn1mXaGOC6VfoXJXklhkuz3RzD-aHmVGiJjpaGPJAbNOO5tz7gMvlHTOZQ6GKQZomIHHCpYXLlRdeOts1WsD6f_s92xAnwETgNiwdWjOFyZVGYbJSQEy9zo0rh5MZFKlidAjkm_gdOPJN1vq6lNbZlxDOCdU9uA_x_uUXN0_PjwwB2-O3j0k17ClS5x8RLaX8_PwGIK5pXvSfqy_AcKlR-s |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Humoral+and+cellular+responses+to+spike+of+%CE%B4+SARS-CoV-2+variant+in+vaccinated+patients+with+immune-mediated+inflammatory+diseases&rft.jtitle=International+journal+of+infectious+diseases&rft.au=Petrone%2C+Linda&rft.au=Picchianti-Diamanti%2C+Andrea&rft.au=Sebastiani%2C+Gian+Domenico&rft.au=Aiello%2C+Alessandra&rft.date=2022-08-01&rft.pub=The+Author%28s%29.+Published+by+Elsevier+Ltd+on+behalf+of+International+Society+for+Infectious+Diseases&rft.issn=1201-9712&rft.eissn=1878-3511&rft.volume=121&rft.spage=24&rft.epage=30&rft_id=info:doi/10.1016%2Fj.ijid.2022.04.027&rft_id=info%3Apmid%2F35462039&rft.externalDocID=PMC9023365 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1201-9712&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1201-9712&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1201-9712&client=summon |